News Column

Cantargia AB: Cantargia's Share Issue of 20 MSEK Fully Subscribed

July 21, 2014

By a News Reporter-Staff News Editor at Clinical Trials Week -- The completed share issue in Cantargia AB, directed to the shareholders in Lund University Bioscience AB, were fully subscribed. The share issue raises approximately 20 MSEK for Cantargia. Cantargia develops a unique pharmaceutical for leukemia, in which the cancer stem cells are killed and thereby eradicating the leukemia. The capital raised will enable Cantargia to start the final development steps for the drug, including toxicology, before initiating clinical trials (see also Cantargia AB).

Cantargia's project has created international interest and the company is currently discussing collaborations with potential partners in order to secure the best possible conditions for the further development up to an approved pharmaceutical.

The company recently announced that Goran Forsberg, previously Active Biotech in Lund, has been recruited as the new CEO of Cantargia.

Lars H. Bruzelius, the chairman of the main owner of Cantargia, Lund University Bioscience AB: "The company is, through the recruitment of Goran Forsberg as CEO, the reinforced board of directors since the beginning of 2014, and the completed share issue, well positioned to continue driving this unique pharmaceutical project forward."

Cantargia AB

The Board of Directors

Keywords for this news article include: Chemicals, Chemistry, Bioscience, Cantargia AB.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC

For more stories on investments and markets, please see HispanicBusiness' Finance Channel

Source: Clinical Trials Week

Story Tools Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters